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without comorbid depression in the US in 2001. METHODS:
Retrospective case-control analysis was conducted of the 2001
Medical Expenditure Panel Survey. In 2001, 32,122 persons
from the US civilian noninstitutionalized population were sur-
veyed. A total of 1101 patients 18 years or older with chronic
obstructive pulmonary disease were identiﬁed. Cases and con-
trols were identiﬁed using ICD-9 codes. The data contained 153
cases with chronic obstructive pulmonary disease and depression
and 948 similar patients without comorbid depression. Cases
were matched at a 1 :1 ratio to controls based on age, race,
gender, and number of comorbidities apart from depression. 
The matching procedure resulted in 145 pairs. Sample estimates
were projected to the population. Expenditure variables repre-
sent sums of all annual out-of-pocket expenditures and third
party payments. Differences in resource use and expenditures
between cases and controls were examined using t-tests. Data
were analyzed using SAS Version 8.2. RESULTS: Patients with
chronic obstructive pulmonary disease and comorbid depression
had higher average total health care expenditures ($10,845 vs.
$6,430; p = 0.0231), expenditures for prescription medications
($2,643 vs. $1574; p = 0.0007), use of ofﬁce-based visits (15.5
vs. 9.4; p = 0.0027), and number of annual prescription med-
ications purchased (45.8 vs. 27.9; p = 0.0001) than the control
group. Net incremental expenditures associated with comorbid
depression were $7,030,575,677 for total health care and
$1,698,632,604 for prescription medications. CONCLUSIONS:
Total health care expenditures were 1.7 times higher for patients
with chronic obstructive pulmonary disease and comorbid
depression than for similar patients without depression matched
on age, gender, race, and number of comorbidities. Depression
in conjunction with chronic obstructive pulmonary is associated
with considerable health care expenditures and utilization of
ofﬁce-based services and prescription medications.
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OBJECTIVES: The prevalence of chronic obstructive pulmonary
disease (COPD) in Hong Kong has been estimated to be 0.35 per
1000 population. The cost of management can therefore trans-
late into an enormous burden on the health care budget. Current
pharmacotherapy includes bronchodilators plus anticholinergics.
Patient compliance can be a problem due to multiple daily
dosing, hence the present study aims to evaluate the potential
beneﬁts of tiotropium with once-daily dosage. METHODS: The
cost of management of COPD was estimated by retrospective
review of the history of a cohort of COPD patients admitted to
the Prince of Wales Hospital (PWH) in Hong Kong from January
1, 2001 to December 31, 2001. Cost items included hospital-
ization, procedures, laboratory tests, medications and outpatient
clinic visits. The cost-effectiveness (CE) model for COPD devel-
oped by Boehringer-Ingelheim was used to assess the CE of
COPD therapies. All analysis was based on local cost data, and
probabilities of events and efﬁcacy data of tiotropium were
adopted from overseas published randomized controlled trials as
there is yet no local published data. The study was performed
from the perspective of a public hospital. RESULTS: Data of 30
patients admitted to the PWH due to COPD were analyzed with
the model. Compared to ipratropium, the once-daily dosage of
tiotropium showed a decrease in number of exacerbations (0.89
vs. 1.21), a decrease in the management cost due to exacerba-
tions (US$2550 vs. 4183) and the cost per exacerbation avoided
due to tiotropium was US$4278. CONCLUSION: Based on 
our preliminary results, tiotropium appears to be a more cost-
effective agent in the treatment of COPD when compared to
ipratropium.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is
a major cause of death and disability throughout the world. The
objective of this study was to evaluate the health/economics 
consequence of four treatments (tiotropium, ipratropium, sal-
meterol and usual care) for patients with COPD in Japan.
METHODS: In order to estimate the patient’s prognosis for one
year, we constructed a Markov model based on the model devel-
oped by Oosenbrink J et al. in Netherlands. Three Markov stages
were set based on the degree of patient’s symptoms, e.g., mod-
erate, severe, and very severe. Acute exacerbation was also
included in the model. Transition probabilities were derived from
several clinical trials. The duration of remaining in the moder-
ate stage was used to deﬁne effectiveness. This study was con-
ducted from the payer’s perspective and only direct medical costs 
were considered. Since the time horizon was one year, discount-
ing was not considered. RESULTS: The expected costs for
tiotropium, ipratropium, salmeterol and usual care were
JPY559,314, JPY771,395, JPY612,707 and JPY621,400, respec-
tively ($1 = JPY103.84). The periods of duration of remaining
in the moderate stage (months) were 8.09, 5.56, 6.99 and 6.43,
respectively. The numbers of acute exacerbation were 0.80, 1.19,
0.96 and 0.91, respectively. A sensitivity analysis on the proba-
bility of home oxygen therapy during maintenance therapy also
showed that the tiotropium was the most cost-effective treat-
ment. CONCLUSION: In spite of the highest daily drug cost,
tiotropium is a cost-saving therapy for treatment of COPD
patients in Japan.
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OBJECTIVES: Most adherence studies have focused on oral
medications, with less attention on diseases where non-oral
routes of administration are predominant. Our objective was to
estimate adherence in VA patients using medications for chronic
respiratory disease and examine factors related to adherence.
METHODS: We identiﬁed patients treated at Chicago-area VAs
that ﬁlled at least two respiratory medications between 08/2002
and 07/2003 (baseline period). We calculated medication pos-
session ratios (MPRs) for each class of respiratory medication
between 08/2003 and 07/2004 (study period) that patients ﬁlled
during the baseline period. Patients were classiﬁed as having
asthma, COPD, combined asthma and COPD (CAC) or none
based on diagnoses at baseline. Average MPR for each medica-
tion category was calculated and logistic regression was used to
identify factors associated with MPRs of >= 75%. RESULTS:
There were 7511 patients included (96.7% male, 35% white).
The number of patients by disease were: COPD = 3721 (49.5%);
asthma = 1045 (13.9%); CAC = 726 (9.7%) and none = 2019
